Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The influenza and respiratory syncytial virus (RSV) combination vaccine is an inhalable mucosal vaccine candidate under development by ISR Vaccine AB, with participation from Icosagen. Designed for intranasal or inhalable administration, the vaccine aims to elicit mucosal immune responses in the respiratory tract, providing a first line of defense against infection by both influenza and RSV. This approach is intended to offer a needle-free alternative to traditional vaccines while potentially providing superior protection against viral transmission by targeting the site of entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine + respiratory syncytial virus vaccine (ISR Vaccine AB).